Does the media refer more to TTRX or PCRX?

In the previous week, Pacira BioSciences had 7 more articles in the media than Turn Therapeutics. MarketBeat recorded 10 mentions for Pacira BioSciences and 3 mentions for Turn Therapeutics. Pacira BioSciences' average media sentiment score of 0.94 beat Turn Therapeutics' score of 0.42 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TTRX or AMPH?

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 3 mentions for Turn Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.69 beat Turn Therapeutics' score of 0.42 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TTRX or IVA?

Turn Therapeutics has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A Inventiva $4.48M 186.26 -$400.67M N/A N/A

Is TTRX or IVA more profitable?

Inventiva's return on equity of 0.00% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Inventiva N/A N/A N/A

Does the media refer more to TTRX or IVA?

In the previous week, Inventiva had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Turn Therapeutics. Inventiva's average media sentiment score of 0.81 beat Turn Therapeutics' score of 0.42 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARDX or TTRX more profitable?

Turn Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -12.35% -36.00% -10.77% Turn Therapeutics N/A -230.84% -53.19%

Does the media refer more to ARDX or TTRX?

In the previous week, Ardelyx and Ardelyx both had 3 articles in the media. Ardelyx's average media sentiment score of 0.88 beat Turn Therapeutics' score of 0.42 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, TTRX or SGP?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is TTRX or SGP more profitable?

Spyglass Pharma's return on equity of -62.40% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Spyglass Pharma N/A -62.40% -24.83%

Does the media refer more to TTRX or SGP?

In the previous week, Turn Therapeutics and Turn Therapeutics both had 3 articles in the media. Spyglass Pharma's average media sentiment score of 0.62 beat Turn Therapeutics' score of 0.42 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Turn Therapeutics (TTRX) Competitors

$12.69 -0.69 (-5.16%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.60 -0.08 (-0.67%)

As of 09/11/2026 07:41 PM Eastern

Compare

TTRX vs. PCRX, AMPH, IVA, ARDX, and SGP

Should you buy Turn Therapeutics stock or one of its competitors? Turn Therapeutics's main competitors and comparable companies include Pacira BioSciences (PCRX), Amphastar Pharmaceuticals (AMPH), Inventiva (IVA), Ardelyx (ARDX), and Spyglass Pharma (SGP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Turn Therapeutics compare to Pacira BioSciences?

Turn Therapeutics (NASDAQ:TTRX) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Pacira BioSciences has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.35	72.46

Turn Therapeutics presently has a consensus price target of $8.00, indicating a potential downside of 36.96%. Pacira BioSciences has a consensus price target of $29.83, indicating a potential upside of 17.64%. Given Pacira BioSciences' higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pacira BioSciences	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Pacira BioSciences had 7 more articles in the media than Turn Therapeutics. MarketBeat recorded 10 mentions for Pacira BioSciences and 3 mentions for Turn Therapeutics. Pacira BioSciences' average media sentiment score of 0.94 beat Turn Therapeutics' score of 0.42 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 1.96% compared to Turn Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Pacira BioSciences	1.96%	9.68%	5.30%

99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pacira BioSciences beats Turn Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Amphastar Pharmaceuticals?

Turn Therapeutics (NASDAQ:TTRX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 3 mentions for Turn Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.69 beat Turn Therapeutics' score of 0.42 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics presently has a consensus target price of $8.00, suggesting a potential downside of 36.96%. Amphastar Pharmaceuticals has a consensus target price of $22.50, suggesting a potential downside of 5.38%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Turn Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Amphastar Pharmaceuticals has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Amphastar Pharmaceuticals	$719.89M	1.41	$98.09M	$1.69	14.07

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amphastar Pharmaceuticals beats Turn Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Inventiva?

Turn Therapeutics (NASDAQ:TTRX) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Inventiva's return on equity of 0.00% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Inventiva	N/A	N/A	N/A

19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Turn Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Inventiva	$4.48M	186.26	-$400.67M	N/A	N/A

Turn Therapeutics currently has a consensus target price of $8.00, suggesting a potential downside of 36.96%. Inventiva has a consensus target price of $15.38, suggesting a potential upside of 282.46%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

In the previous week, Inventiva had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Turn Therapeutics. Inventiva's average media sentiment score of 0.81 beat Turn Therapeutics' score of 0.42 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inventiva beats Turn Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Turn Therapeutics has lower revenue, but higher earnings than Ardelyx. Turn Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	2.19	-$61.60M	-$0.22	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Turn Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Turn Therapeutics	N/A	-230.84%	-53.19%

Ardelyx currently has a consensus price target of $13.90, indicating a potential upside of 288.27%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential downside of 36.96%. Given Ardelyx's stronger consensus rating and higher possible upside, research analysts plainly believe Ardelyx is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

58.9% of Ardelyx shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Ardelyx and Ardelyx both had 3 articles in the media. Ardelyx's average media sentiment score of 0.88 beat Turn Therapeutics' score of 0.42 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ardelyx beats Turn Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Spyglass Pharma?

Turn Therapeutics (NASDAQ:TTRX) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Turn Therapeutics and Turn Therapeutics both had 3 articles in the media. Spyglass Pharma's average media sentiment score of 0.62 beat Turn Therapeutics' score of 0.42 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential downside of 36.96%. Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 59.88%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Spyglass Pharma's return on equity of -62.40% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Spyglass Pharma	N/A	-62.40%	-24.83%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Summary

Spyglass Pharma beats Turn Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$398.56M	$12.44B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-43.76	799.75	275.24	25.29
Price / Sales	N/A	763.36	655.99	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	79.31	10.39	10.33	6.20
Net Income	-$3.19M	$2.85B	$3.50B	$358.50M
7 Day Performance	29.49%	-3.61%	-3.32%	-2.35%
1 Month Performance	20.40%	0.86%	-0.41%	-2.77%
1 Year Performance	N/A	3.47%	19.21%	7.63%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	1.5233 of 5 stars	$12.69 -5.2%	$8.00 -37.0%	N/A	$398.56M	N/A	N/A	2
PCRX Pacira BioSciences	3.4617 of 5 stars	$26.60 +0.1%	$30.20 +13.5%	-6.2%	$1.06B	$726.41M	76.00	720	News Coverage Positive News Analyst Forecast
AMPH Amphastar Pharmaceuticals	1.8722 of 5 stars	$23.84 +0.4%	$22.50 -5.6%	-17.1%	$1.01B	$719.89M	14.11	1,976	News Coverage Analyst Downgrade
IVA Inventiva	2.2758 of 5 stars	$4.84 -0.4%	$15.38 +217.7%	-30.3%	$1.01B	$5.07M	N/A	100	Gap Up
ARDX Ardelyx	2.9378 of 5 stars	$3.71 -2.4%	$13.90 +274.7%	-46.4%	$946.91M	$407.32M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. PCRX, AMPH, IVA, ARDX, and SGP

How does Turn Therapeutics compare to Pacira BioSciences?

Summary

How does Turn Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Turn Therapeutics compare to Inventiva?

Summary

How does Turn Therapeutics compare to Ardelyx?

Summary

How does Turn Therapeutics compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. PCRX, AMPH, IVA, ARDX, and SGP

How does Turn Therapeutics compare to Pacira BioSciences?

Which has higher valuation and earnings, TTRX or PCRX?

Do analysts prefer TTRX or PCRX?

Does the media refer more to TTRX or PCRX?

Is TTRX or PCRX more profitable?

Do institutionals and insiders hold more shares of TTRX or PCRX?

Summary

How does Turn Therapeutics compare to Amphastar Pharmaceuticals?

Does the media refer more to TTRX or AMPH?

Do analysts prefer TTRX or AMPH?

Is TTRX or AMPH more profitable?

Which has better earnings & valuation, TTRX or AMPH?

Do institutionals and insiders have more ownership in TTRX or AMPH?

Summary

How does Turn Therapeutics compare to Inventiva?

Is TTRX or IVA more profitable?

Do institutionals and insiders hold more shares of TTRX or IVA?

Which has preferable valuation and earnings, TTRX or IVA?

Do analysts recommend TTRX or IVA?

Does the media refer more to TTRX or IVA?

Summary

How does Turn Therapeutics compare to Ardelyx?

Which has better earnings and valuation, ARDX or TTRX?

Is ARDX or TTRX more profitable?

Do analysts rate ARDX or TTRX?

Do institutionals & insiders hold more shares of ARDX or TTRX?

Does the media refer more to ARDX or TTRX?

Summary

How does Turn Therapeutics compare to Spyglass Pharma?

Does the media refer more to TTRX or SGP?

Do analysts rate TTRX or SGP?

Is TTRX or SGP more profitable?

Which has stronger earnings and valuation, TTRX or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools